Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Shionogi’s year-long studies of obesity drug meet endpoint
Shionogi assessed the long-term efficacy and safety of velneperit over the course of one year in two distinct studies, comprising a total randomized population of 1,566 obese subjects
Shionogi assessed the long-term efficacy and safety of velneperit over the course of one year in two distinct studies, comprising a total randomized population of 1,566 obese subjects
Robert McCullough, chief executive officer (CEO) of CytoCore, commented, “This agreement with Synermed allows CytoCore to offer physicians and laboratories the Synermed Preservative with our SoftPAP® cervical cell
Small Bone Innovations Deutschland (SBi Deutschland) is based in Donaueschingen. SBi is in the process of re-launching the Scandinavian Total Ankle Replacement (STAR) under the SBi brand, and
The company will use the funding to complete the pivotal Phase III clinical development program for its lead product candidate, Myocet. Myocet is a liposomal formulation of doxorubicin
Net loss for the year ended December 31, 2008 was $8.5 million, or $0.16 per diluted share, compared to a net loss of $18.3 million, or $0.35 per
The product will be marketed under store brand labels and is comparable to Wyeth Consumer Healthcare’s Advil PM tablets, 200/38mg, indicated as a pain reliever non-steroidal anti-inflammatory drug/nighttime
Investors also received 0.75 of a warrant, exercisable at a price of $2.15 per share, for each share of common stock. The warrants have a three-year term from
Richard Garr, president and CEO of Neuralstem, said: “The FDA has presented us with their review of our entire investigational new drug application. They have asked for some
According to Revolutions Medical, the Rev Vac safety syringe uses patented technology to draw the needle back into the syringe chamber after use. This safety syringe is expected
The Phase I study will assess the safety, pharmacokinetics and anti-tumor activity of NKTR-105 in approximately 30 patients with refractory solid tumors who have failed all prior available